# Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

Source: https://onco.cc/trials/nct07786428/  
OnCo record `nct07786428` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by University of Texas Southwestern Medical Center, not yet recruiting.

## Summary

Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC is a phase 2, randomised interventional study registered as NCT07786428 by University of Texas Southwestern Medical Center, with a registry enrolment figure of 60 participants, started 2026-10-01 and due to reach its primary completion in 2029-10-31. Interventions recorded: Pembrolizumab; Paclitaxel (Chemotherapy); Carboplatin. Conditions listed: Triple-Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "* Must have histologically confirmed invasive triple negative breast cancer as defined by ER/PR \<10% and HER2 negative by ASCO/CAP criteria or disease consistent with TNBC by physician assessment, with confirmation by study PI". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: DETENTE-1
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07786428
- Phase: 2
- Setting: A Phase 2 Randomized Pilot Study to Develop Tailored Neoadjuvant Chemoimmunotherapy Strategies in Stage I Triple-negative Breast Cancer (DETENTE-1)
- Sponsor: University of Texas Southwestern Medical Center
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07786428: https://clinicaltrials.gov/study/NCT07786428

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07786428.json